Key result
A history of cancer at the time of PCI was associated with an increased risk of cardiac death (HR 1.27; 95% CI 1.05-1.53; P=0.02) and heart failure hospitalization.
Why the study?
Does a history of cancer increase the risk of adverse cardiovascular outcomes in CAD patients undergoing PCI?
Cohort (n=12,180)
Does a history of cancer increase the risk of adverse cardiovascular outcomes in CAD patients undergoing PCI?
Hazard Ratio: 1.27 (95% CI 1.05–1.53)
Absolute Event Rate: 12.4% vs 7.5%
p-value: p=0.02
A history of cancer in patients undergoing PCI is associated with an increased long-term risk of cardiac death, heart failure hospitalization, and major bleeding.
May prompt enhanced post-PCI surveillance in cancer patients; hypothesis-generating for adjusted risk models and targeted trials.
Aims: To evaluate the influence of a history of cancer on clinical outcomes in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Methods and results: In the Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/coronary artery bypass grafting (CABG) Registry Cohort-2, there were 12 180 CAD patients who received PCI with stents. There were 1109 patients with a history of cancer (cancer group) and 11 071 patients without cancer (non-cancer group). The cumulative 5-year incidences of cardiac death and heart failure (HF) hospitalization were significantly higher in the cancer group than in the non-cancer group (12.4% vs. 7.5%, P < 0.001 and 12.1% vs. 7.6%, P < 0.001, respectively). Even after adjusting for confounders, the excess risk of the cancer group relative to non-cancer group for cardiac death and HF hospitalization remained significant [hazard ratio (HR) 1.27, 95% confidence interval (95% CI) 1.05-1.53; P = 0.02, and HR 1.39, 95% CI 1.13-1.68; P = 0.002, respectively]. Also, the cancer group had a trend toward higher adjusted risk for definite or probable stent thrombosis as compared with the non-cancer group (HR 1.49, 95% CI 0.99-2.16; P = 0.055). The cancer group had significantly higher adjusted risk for all-cause death, non-cardiac death, major bleeding, and non-CABG surgery than the non-cancer group, while the risks for myocardial infarction and stroke were neutral between the two groups. Conclusion: Patients with a history of cancer at the time of PCI had increased risk for cardiac events such as cardiac death and HF hospitalization as well as non-cardiac events such as non-cardiac death, major bleeding, and non-CABG surgery.
No takes yet. Share an insight, caveat, or question.
Nakatsuma et al. (2018) conducted a cohort in Coronary artery disease (CAD) (n=12,180). History of cancer vs. No history of cancer was evaluated on Cardiac death (HR 1.27, 95% CI 1.05-1.53, p=0.02). A history of cancer at the time of PCI was associated with an increased risk of cardiac death (HR 1.27; 95% CI 1.05-1.53; P=0.02) and heart failure hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: